These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The place of ifosfamide in chemotherapy of small cell lung cancer: the Eastern Cooperative Oncology Group experience and a selected literature update.
    Author: Ettinger DS.
    Journal: Semin Oncol; 1995 Feb; 22(1 Suppl 2):23-7. PubMed ID: 7846538.
    Abstract:
    In a randomized Eastern Cooperative Oncology Group study, single-agent ifosfamide used to treat extensive-disease small cell lung cancer patients produced a 49% response rate compared with 56% for patients receiving standard combination chemotherapy (cyclophosphamide/doxorubicin/vincristine). When the drug was combined with carboplatin and etoposide to treat extensive-disease small cell lung cancer patients, overall response rate was 83%, median survival time was 9 months, and 2-year survival rate was 14%. The major toxicity was myelosuppression. These results confirm those of other investigators who have shown the effectiveness of the ifosfamide/carboplatin/etoposide regimen in treating patients with small cell lung cancer.
    [Abstract] [Full Text] [Related] [New Search]